Showing 691-700 of 737 results for "".
- AI in Action: Almirall, Barcelona Supercomputing Center, and Nostrum Biodiscovery Seek New Dermatologic Therapies via AIhttps://practicaldermatology.com/news/ai-in-action-almirall-barcelona-supercomputing-center-bsc-and-nostrum-biodiscovery-seek-new-dermatologic-therapies-via-ai/2462171/Almirall S.A. (BME: ALM), Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) and Nostrum Biodiscovery are joining forces to explore artificial intelligence (AI) and machine learning (ML) generative approaches to design new protein-protein modulators for dermatolo
- Is Lower Extremity Lymphedema a Risk for Skin Cancer?https://practicaldermatology.com/news/is-lower-extremity-lymphedema-a-risk-for-skin-cancer/2462127/Patients with lymphedema may have twice the risk of developing basal cell carcinomas and squamous cell carcinomas on the lower extremities than their counterparts without lymphedema, according to a retrospective study published in the November 2023 issue of the Mayo Clinic Proceedings.&n
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co. Ltd. for Qbrexza in South Korea, Other Asian Nationshttps://practicaldermatology.com/news/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd-for-qbrexza-in-south-korea-other-asian-nations/2461983/Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations. Maruho Co., Ltd. is Journey’s exclusive licensing partner that developed and is commercializing Qbrexza (Rapifort) in Japan.&n
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of&n
- New Class of Immunotherapy Drugs May Fight Melanomahttps://practicaldermatology.com/news/new-class-of-immunotherapy-drugs-may-fight-melanoma/2461682/A new class of immunotherapy shows promising results for fighting melanoma, a new study shows. The study, published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a n
- Baby Dove Launches #BabySkin Advice on TikTok with Top Dermatologists and Pediatricianshttps://practicaldermatology.com/news/baby-dove-launches-babyskin-advice-on-tiktok-with-top-dermatologists-and-pediatricians/2461582/Baby Dove is launching #BabySkin Advice,' on TikTok The series provides expert advice from dermatologists and pediatricians to help parents in search of trusted products to care for their newborns unique and delicate skin needs. The #BabySkin Advice series will run from&n
- Laura Geller Beauty's Signature Foundation Scores the National Psoriasis Foundation's Seal of Recognitionhttps://practicaldermatology.com/news/laura-geller-beautys-signature-foundation-scores-the-national-psoriasis-foundations-seal-of-recognition/2461533/The National Psoriasis Foundation granted its Seal of Recognition to Laura Geller Beauty's Signature Baked Balance-n-Brighten Color Correcting Foundation. This is the first makeup product to receive the National Psoriasis Foundation Seal of Recognition.
- Zubin Meshginpoosh Named President and COO at Sentéhttps://practicaldermatology.com/news/zubin-meshginpoosh-named-president-and-coo-at-sente/2461463/Zubin Meshginpoosh is now the President and Chief Operational Officer of Senté. "Zubin has an incredible track record for enabling teams to achieve success in high growth and fast-changing environments," says Faheem Hasnain, Chairman of the Board at Senté, in a n
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once dai
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n